Healthcare Stocks Trade Higher: INO Surges 245%, IDXX Gains Over 20%, TEM Rises 12%
INOVIO (INO) surged 245% after FDA accelerated approval for VOCERYQ. IDEXX (IDXX) rose 20% on strong Q3 earnings and raised guidance. Tempus AI (TEM) gained 12% with Q3 revenue up 23% and narrowed losses. VOCERYQ targets HPV-related RRP, with commercial launch planned for Q1 2027.
How this was made
The 30-second read
Why it matters
The combined news creates a short‑term bullish bias for the highlighted companies and may lift sector sentiment.
Market read
All three stocks experienced double‑digit gains on the day, indicating strong market reaction to the news.
What to watch
Potential pricing negotiations with payors and the need for post‑approval study results could limit upside.
Background
The article summarizes recent FDA approval for INOVIO and Q3 earnings for IDEXX and Tempus AI, all driving notable price moves in healthcare stocks.
Ticker impact
FDA granted accelerated approval for INOVIO's VOCERYQ therapy, driving a 245% stock surge.
likely upward pressure as investors buy on the approval news
Approval is a material catalyst for a biotech with no prior market pricing; the move is already large and may attract further buying.
IDEXX reported Q3 2026 earnings beating prior year and raised full‑year revenue guidance.
moderate upside as investors digest stronger earnings and higher guidance
Revenue and EPS beat are fresh data; guidance lift adds incremental upside but the move is already reflected in the price.
Tempus AI posted Q3 2026 results, narrowing loss and raising full‑year revenue guidance.
moderate upside as the market rewards narrowing losses and revenue growth
Guidance raise is new information; the stock already rose, but further buying is plausible.
Market effects
Positive FDA approval may boost the broader biotech and gene‑therapy sector.
U.S. healthcare stocks rallied, supporting the Nasdaq health‑care index.
Approval highlights U.S. regulatory progress, potentially influencing global biotech valuations.
Counterpoint
If post‑approval data fails to confirm clinical benefit, the stock could face a sharp correction.
Key entities
- CompanyINOVIO Pharmaceuticals
Biotech receiving FDA accelerated approval for VOCERYQ.
- CompanyIDEXX Laboratories
Veterinary diagnostics firm reporting earnings beat and raised guidance.
- CompanyTempus AI
Data‑driven healthcare company reporting narrowed loss and higher revenue outlook.
